CRKL amplification is rare as a mechanism for acquired resistance to kinase inhibitors in lung cancers with epidermal growth factor receptor mutation

Lung Cancer

Volumn 85, Issue 2, 2014, Pages 147-151

  Suda, Kenichi ^a   Mizuuchi, Hiroshi ^a   Murakami, Isao ^b   Uramoto, Hidetaka ^c   Tanaka, Fumihiro ^c   Sato, Katsuaki ^a   Takemoto, Toshiki ^a   Iwasaki, Takuya ^a   Sekido, Yoshitaka ^d   Yatabe, Yasushi ^d   Mitsudomi, Tetsuya ^a  

^a KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Saijo cho   (Japan)

^c UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

^d AICHI CANCER CENTER HOSPITAL   (Japan)

Author keywords

Acquired resistance; EGFR mutation; Erlotinib; Gefitinib; MET gene amplification; Molecular target therapy; T790M mutation

Indexed keywords

CRK LIKE PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE INHIBITOR; NUCLEAR PROTEIN; PROTEIN KINASE INHIBITOR; SCATTER FACTOR RECEPTOR; SIGNAL TRANSDUCING ADAPTOR PROTEIN;

ADENOCARCINOMA CELL LINE; ADULT; AGED; ANEUPLOIDY; ARTICLE; AUTOPSY; CANCER PATIENT; CANCER RESISTANCE; CODON; EOSINOPHILIC LEUKEMIA; FEMALE; FOLLOW UP; GASTROINTESTINAL STROMAL TUMOR; GENE AMPLIFICATION; GENE DOSAGE; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; LUNG CANCER; MALE; MIDDLE AGED; MOLECULARLY TARGETED THERAPY; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; VERY ELDERLY; CANCER STAGING; DRUG RESISTANCE; GENETICS; LUNG NEOPLASMS; MORTALITY; MUTATION; PATHOLOGY; PROGNOSIS; RISK FACTOR;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; AGED; AGED, 80 AND OVER; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE AMPLIFICATION; GENE DOSAGE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; NEOPLASM STAGING; NUCLEAR PROTEINS; PROGNOSIS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-MET; RECEPTOR, EPIDERMAL GROWTH FACTOR; RISK FACTORS;

EID: 84904110115     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2014.05.018     Document Type: Article

References (20)

1. Suda K., Mitsudomi T. Development of personalized treatments in lung cancer: focusing on the EGFR mutations and beyond. Lung Cancer: Targets Ther 2013, 4:43-53.
2. Kobayashi S., Boggon T.J., Dayaram T., Janne P.A., Kocher O., Meyerson M., et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 2005, 352:786-792.
3. Pao W., Miller V.A., Politi K.A., Riely G.J., Somwar R., Zakowski M.F., et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2005, 2:e73.
4. Engelman J.A., Zejnullahu K., Mitsudomi T., Song Y., Hyland C., Park J.O., et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007, 316:1039-1043.
5. Bean J., Brennan C., Shih J.Y., Riely G., Viale A., Wang L., et al. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci USA 2007, 104:20932-20937.
6. Yano S., Wang W., Li Q., Matsumoto K., Sakurama H., Nakamura T., et al. Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations. Cancer Res 2008, 68:9479-9487.
7. Suda K., Tomizawa K., Fujii M., Murakami H., Osada H., Maehara Y., et al. Epithelial to mesenchymal transition in an epidermal growth factor receptor-mutant lung cancer cell line with acquired resistance to erlotinib. J Thorac Oncol 2011, 6:1152-1161.
8. Uramoto H., Shimokawa H., Hanagiri T., Kuwano M., Ono M. Expression of selected gene for acquired drug resistance to EGFR-TKI in lung adenocarcinoma. Lung Cancer 2011, 73:361-365.
9. Sequist L.V., Waltman B.A., Dias-Santagata D., Digumarthy S., Turke A.B., Fidias P., et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 2011, 3:75ra26.
10. Zhang Z., Lee J.C., Lin L., Olivas V., Au V., LaFramboise T., et al. Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer. Nat Genet 2012, 44:852-860.
11. Takezawa K., Pirazzoli V., Arcila M.E., Nebhan C.A., Song X., de Stanchina E., et al. HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation. Cancer Discov 2012, 2:922-933.
12. Yu H.A., Arcila M.E., Rekhtman N., Sima C.S., Zakowski M.F., Pao W., et al. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res 2013, 19:2240-2247.
13. Cheung H.W., Du J., Boehm J.S., He F., Weir B.A., Wang X., et al. Amplification of CRKL induces transformation and epidermal growth factor receptor inhibitor resistance in human non-small cell lung cancers. Cancer Discov 2011, 1:608-625.
14. Suda K., Murakami I., Katayama T., Tomizawa K., Osada H., Sekido Y., et al. Reciprocal and complementary role of MET amplification and EGFR T790M mutation in acquired resistance to kinase inhibitors in lung cancer. Clin Cancer Res 2010, 16:5489-5498.
15. Jackman D., Pao W., Riely G.J., Engelman J.A., Kris M.G., Janne P.A., et al. Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. J Clin Oncol 2010, 28:357-360.
16. Therasse P., Arbuck S.G., Eisenhauer E.A., Wanders J., Kaplan R.S., Rubinstein L., et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000, 92:205-216.
17. Zhao X., Weir B.A., LaFramboise T., Lin M., Beroukhim R., Garraway L., et al. Homozygous deletions and chromosome amplifications in human lung carcinomas revealed by single nucleotide polymorphism array analysis. Cancer Res 2005, 65:5561-5570.
18. Suda K., Mitsudomi T. Pten - a molecule that cancers abuse to overcome their achilles heels. PTEN structure, mechanisms-of-action, role in cell signaling and regulation 2013, 101-117. Nova Science Publishers, New York. 1st ed. Ke Xu (Ed.).
19. Straussman R., Morikawa T., Shee K., Barzily-Rokni M., Qian Z.R., Du J., et al. Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature 2012, 487:500-504.
20. Bardelli A., Corso S., Bertotti A., Hobor S., Valtorta E., Siravegna G., et al. Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer. Cancer Discov 2013, 3:658-673.